The Translational Pathology Core has been continuously under the leadership of Dr. Sue Ellen Martin since its founding in 1998. This NCI-funded Shared Resource provides a single point of access for Cancer Center members needing tissue procurement and banking services.
The specific aims of the Core are to: 1) procure, bank, process, track, and distribute both fresh/frozen and formalin-fixed, paraffin embedded (FFPE) normal and tumor tissue biospecimens necessary for laboratory-based, epidemiological, and hospital-based clinical studies being conducted by USC Norris Cancer Center members; 2) procure, maintain, and track discarded FFPE tumor tissue blocks from local regional hospitals identified through the Cancer Surveillance Program (CSP) for the population-based LA Residual Tissue Repository (RTR), which corresponds directly to the catchment area; 3) ensure that all studies utilizing tissue have appropriate documented IRB approval and that protected health information (PHI) is not released unless there is a signed written Informed Consent; and 4) incorporate innovations in tissue procurement and banking methodology to meet investigator-led research. The Core continues to have three components, or Arms: Adult, Pediatric and Population-Based. Together, these Arms provide an integrated, single stop service. Accomplishments during the project period include: 1) increased usage by Cancer Center members with peerreviewed grants. In the most recent reporting year (FY 2013-2014), 91 Cancer Center members used the Core, of which 53 (58%) had peer-reviewed funding. This is an increase of 140%, from the prior project period; 2) higher chargebacks. User fees account for 27% of the total budget, up from 17% over the project period; and 3) increased collection and distribution of both fresh/frozen and FFPE tissues. This has contributed to significant research advances by Cancer Center members in understanding of the mechanisms involved in carcinogenesis, particularly in gastric, colorectal, urothelial and lung cancers, neuroblastoma and Hodgkin?s lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-45
Application #
9838171
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48

Showing the most recent 10 out of 842 publications